Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Vemurafenib and TIL Therapy for Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02354690
Recruitment Status : Completed
First Posted : February 3, 2015
Results First Posted : February 24, 2020
Last Update Posted : March 23, 2020
Information provided by (Responsible Party):
Inge Marie Svane, Herlev Hospital

Brief Summary:


Adoptive T cell therapy with tumor infiltrating lymphocytes (TILs) has been reported to induce durable clinical responses in patients with metastatic melanoma. From patients own tumor material T cells are extracted, expanded and activated in vitro in a 4-6 weeks culture period. Before TIL infusion patients are preconditioned with a lymphodepleting chemotherapeutic regimen. After TIL infusion, patients are treated with IL-2 to support T cell activation and expansion in vivo.

The BRAF inhibitor is an approved treatment of metastatic melanoma and functions by selectively inhibiting the BRAF mutated enzyme, consequently halting the proliferation of tumor cells. Furthermore, in vitro tests have shown that vemurafenib has immunomodulatory effects that are hypothesized to synergize with TIL therapy, which has been confirmed in animal studies.


  • To evaluate safety and feasibility when combining vemurafenib and ACT with TILs.
  • To evaluate treatment related immune responses
  • To evaluate clinical efficacy


  • Patients will be screened with a physical exam, medical history, blood samples and ECG.
  • Patients will start vemurafenib 960 mg BID and will continue during TIL preparation.
  • 7 days after start of vemurafenib, patients will undergo surgery to harvest tumor material for TIL production.
  • Patient stops vemurafenib and is admitted day -8 in order to undergo lymphodepleting chemotherapy with cyclophosphamide and fludara starting day -7.
  • On day 0 patients receive TIL infusion and shortly after starts IL-2 infusion continually following the decrescendo regimen.
  • The patients will followed until progression or up to 5 years.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Drug: Vemurafenib Drug: Lymphodepleting chemotherapy Drug: TIL infusion Drug: Interleukin-2 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma
Actual Study Start Date : November 2014
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma
Drug Information available for: Vemurafenib

Arm Intervention/treatment
Experimental: A
7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
Drug: Vemurafenib
Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
Other Names:
  • Zelboraf
  • BRAF inhibitor

Drug: Lymphodepleting chemotherapy
First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
Other Names:
  • cyclophosphamide
  • fludarabine

Drug: TIL infusion

7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.

On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells).

Other Names:
  • Adoptive cell transfer
  • T cell therapy

Drug: Interleukin-2
After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
Other Name: IL-2

Primary Outcome Measures :
  1. Number of Reported Adverse Events [ Time Frame: 0-40 weeks ]
    Determine the safety of the administration of vemurafenib in combination with TIL therapy including lymphodepleting chemotherapy and interleukin-2 treatment by collecting adverse events according to CTCAE v. 4.0. From start of treatment until 24 weeks after T cell infusion.

Secondary Outcome Measures :
  1. Treatment Related Immune Responses [ Time Frame: 0-24 weeks ]

    Number of patients whose infusion product contained anti-tumor reactive T cells by in vitro testing.

    Anti-tumor reactive T cells is defined by positive staining for two of the three markers (interferon gamma, tumor necrosis factor alpha and CD107a) in an intracellular cytokine staining using flow cytometry.

  2. Objective Response Rate [ Time Frame: Up to 12 months ]
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

  3. Overall Survival [ Time Frame: Up to 40 months ]
    Overall survival (OS), defined as the time from the start of treatment to death, will be described with the Kaplan-Meier curve.

  4. Progression Free Survival [ Time Frame: Up to 40 months ]

    Progression-free survival (PFS), defined as the time from start of treatment to disease progression, relapse or death due to any cause, whichever is earlier, will be described with the Kaplan-Meier curve.

    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed unresectable stage III or stage IV metastatic melanoma.
  • Metastasis available for surgical resection (about 2 cm3) and residual measureable disease after resection.
  • Pathologically verified BRAF mutation.
  • ECOG performance status 0-1.
  • Life expectancy ≥ 3 months.
  • No significant toxicity (CTC ≤ 1) from prior treatments.
  • Adequate renal, hepatic and hematologic function.
  • Women of childbearing potential (WOCBP) and men in a sexual relationship with a WOCBP must be using an effective method of contraception during treatment and for at least 6 months after completion of treatment.
  • Able to comprehend the information given and willing to sign informed consent.

Exclusion Criteria:

  • Other malignancies, unless followed for ≥ 5 years with no sign of disease, except squamous cell carcinoma or adequately treated carcinoma in situ colli uteri.
  • Cerebral metastasis. Patients with previously treated CNS metastasis can participate if surgically removed or treated with stereotactic radiotherapy if stable > 28 days after treatment measured by MRI. Patients with asymptomatic and untreated CNS metastasis can participate based on investigators evaluation.
  • Patients with ocular melanoma.
  • Previous treatment with a BRAF inhibitor.
  • Severe allergies, history of anaphylaxis or known allergies to drugs administered.
  • Serious medical or psychiatric comorbidity.
  • QTc ≥ 450 ms.
  • Clearance < 70 ml/min.
  • Acute or chronic infection with e.g. HIV, hepatitis, tuberculosis
  • Active autoimmune disease.
  • Pregnant og nursing women.
  • Need for immunosuppressive treatment, e.g. corticosteroids or methotrexate.
  • Concomitant treatment with other experimental drugs.
  • Patients with uncontrolled hypercalcemia
  • More than four weeks must have elapsed since any prior systemic therapy at the time of treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02354690

Layout table for location information
Center for Cancer Immune Therapy, Dept. of Haematology/Oncology
Copenhagen, Herlev, Denmark, 2730
Sponsors and Collaborators
Inge Marie Svane
Layout table for investigator information
Study Director: Inge Marie Svane, Prof., MD Department of Oncology, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, DK-2730 Herlev, Denmark
Principal Investigator: Troels Holz Borch, MD Department of Oncology, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, DK-2730 Herlev, Denmark
  Study Documents (Full-Text)

Documents provided by Inge Marie Svane, Herlev Hospital:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Inge Marie Svane, Professor, MD, Herlev Hospital Identifier: NCT02354690    
Other Study ID Numbers: MM1414
First Posted: February 3, 2015    Key Record Dates
Results First Posted: February 24, 2020
Last Update Posted: March 23, 2020
Last Verified: March 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Protein Kinase Inhibitors
Enzyme Inhibitors